drugset
drugset / Trial / NCT04178733

A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants

NCT04178733 ↗

Phase 1 Completed 33 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

This study is being conducted to determine the side effects related to LY3493269 given as a single injection to healthy participants. Blood tests will be performed to check how much LY3493269 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of LY3493269 or placebo. The study will last up to approximately 71 days for each participant, including screening.

Timeline

Start
2020-01-10
Primary completion
2020-05-11
Completion
2020-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3493269 Unknown 0.15 mg Subcutaneous
Subject LY3493269 Unknown 0.5 mg Subcutaneous
Subject LY3493269 Unknown 1.5 mg Subcutaneous

Indications

No indication recorded.